Dr. Michael Briejer, Co-Chair

Dr. Michel Briejer is managing partner and joined the venture capital firm Thuja Capital early 2008. He has contributed significantly to building the firm and its successful portfolio of early stage companies in the therapeutics and medical device space.

Prior to joining Thuja, he held senior management positions in drug development both in the international pharmaceutical industry (e.g. Janssen Pharmaceutica, Yamanouchi (currently Astellas Pharma)) as well as in the biotech industry (Crucell). 

Mr Briejer holds an MSc degree in Pharmacy (Utrecht University) and a PhD in Pharmacology (Wageningen University), as well as a post-doctoral degree in Pharmaceutical Medicine (Dip.Phar.Med., European Center for Pharmaceutical Sciences, Basle).